Compare Tempus AI (TEM) vs Viatris Inc (VTRS) Price & Performance

Tempus AITrade

Viatris IncTrade

Price performance (Past 24H)

Key statistics

Tempus AI vs Viatris Inc — how do they compare? Tempus AI trades at $49.05 (market cap $8.69B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 2.3× Tempus AI's market cap, and Viatris Inc pays a 2.83% dividend while Tempus AI pays none. Which is the better fit depends on your goals.

	TEM	VTRS
Market Cap	$8.69B	$19.79B
Sector	Broad Market / Factor	Health
52-Week High	$103.25	$17.39
52-Week Low	$42.37	$8.74
Enterprise Value	$9.37B	$32.00B
Dividend Yield	—	2.83%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

TEM

Needham downgrades Personalis to Hold after $1.5B Tempus AI acquisition deal announcedAlex Lavoie · 1 day agoBearish Law firm probes fairness of Tempus' $16.25/share acquisition offer for Personalis amid conflict concernsGlobeNewsWire · 1 day agoBearish Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B in stock dealProactive Investors · 1 day agoBearish View details →

VTRS

View details →

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).